Clinical Trial Update: Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation [Phase 3]

View source ↗

Summary

AstraZeneca reports long-term safety results from a Phase 3 trial of naloxegol for opioid-induced constipation in adults with non-cancer pain. The results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• MOVANTIK (Naloxegol oxalate)

Snippet

Sponsor: AstraZeneca | Conditions: Opioid-Induced Constipation (OIC) | Phase 3 | Status: COMPLETED | Results posted: 2014-10-20